Stelara Settlement Gives Amgen US Ustekinumab Entry Date

Agreement With Johnson & Johnson’s Janssen Offers Amgen 1 January 2025 Launch Date

 
• By Dave Wallace

A settlement reached in US patent litigation over Janssen’s Stelara will allow Amgen to launch its ABP 654 ustekinumab biosimilar no later than 1 January 2025. It remains to be seen whether other ustekinumab developers will follow suit.

Date Timeline, Blue Pin Next To 2025
Amgen will be able to launch no later than 1 January 2025 • Source: Shutterstock

Litigation launched by Johnson & Johnson’s Janssen over Amgen’s proposed biosimilar rival to Stelara (ustekinumab) has been settled through a deal that will allow Amgen to launch its ABP 654 version in the US no later than 1 January 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products